DNOW Q1 Earnings Call: Margin Resilience and Market Diversification Amid Tariff Uncertainty
Is now the time to buy DNOW? Find out in our full research report (it's free).
Revenue: $599 million vs analyst estimates of $587.8 million (6.4% year-on-year growth, 1.9% beat)
Adjusted EPS: $0.22 vs analyst estimates of $0.17 (26.9% beat)
Adjusted EBITDA: $46 million vs analyst estimates of $40.4 million (7.7% margin, 13.9% beat)
Operating Margin: 5%, in line with the same quarter last year
Market Capitalization: $1.57 billion
DistributionNOW's first quarter results were shaped by steady demand in U.S. midstream infrastructure and continued momentum in the company's Process Solutions segment, despite a largely unchanged U.S. rig count and lower completions activity. Management pointed to resilient gross margins and a diversified market mix as core reasons for outperforming expectations. CEO David Cherechinsky highlighted that the quarter delivered the second-best first quarter EBITDA in company history, noting, 'This is notable given the misunderstood perception that the upstream sector alone drives opportunities for DNOW.' The company's recent acquisition in Singapore further contributed to expansion in the Asia Pacific region and strengthened its MacLean International brand, underscoring the importance of international diversification. Cherechinsky also emphasized the effectiveness of DNOW's supply chain repositioning in response to previous tariff rounds and supply disruptions, which allowed the company to maintain operational flexibility.
Looking ahead, DistributionNOW's outlook hinges on its ability to manage tariff-driven cost pressures, capitalize on U.S. midstream opportunities, and further penetrate adjacent industrial markets. Management reaffirmed full-year revenue guidance with expectations of flat to high-single-digit growth, supported by continued investment in digital initiatives and targeted M&A. Cherechinsky acknowledged ongoing macro uncertainty, driven by evolving tariffs and fluctuating oil prices, stating, 'The dynamics of this environment remain volatile, leading to fluctuations in market sentiment.' The company's strategy includes passing on supplier cost increases, optimizing pricing structures, and leveraging its purchasing power to buffer against inflation and supply chain volatility. While risks remain from potential declines in U.S. rig activity, DNOW anticipates that midstream demand and its inventory planning will help offset upstream headwinds and support earnings stability.
Management attributed first quarter performance to execution in U.S. midstream and Process Solutions, strategic inventory planning, and swift adaptation to tariff and supply chain changes.
Midstream and Process Solutions momentum: Increased activity in U.S. midstream infrastructure and a full-quarter contribution from the Trojan acquisition boosted growth, with Process Solutions delivering its highest-ever quarterly revenue contribution.
Strategic inventory build: The company intentionally increased inventory in anticipation of tariff-related supply disruptions, positioning itself to maintain product availability and optimize procurement costs as tariff impacts unfold.
International expansion with acquisition: The acquisition of a Singapore-based distributor expanded DistributionNOW's MacLean International offering in Asia Pacific, targeting diversified end markets such as marine, petrochemical, and data centers.
Digital transformation progress: DigitalNOW initiatives drove efficiencies, with digital revenue reaching a record 53% of SAP-related sales. Management highlighted the rollout of AI-powered process automation, including certificate indexing and system integration.
Tariff and inflation management: The company's supply chain adjustments reduced dependence on China, with most products sourced domestically or from alternative international suppliers. Management expects to pass on cost increases and adjust pricing to protect margins as new tariffs take effect.
DistributionNOW's forward guidance is shaped by tariff-driven pricing, midstream growth, and ongoing diversification into adjacent markets.
Tariffs and pricing strategy: Management expects recently announced tariffs and supplier cost inflation to drive higher input costs, but plans to pass these through to customers via pricing adjustments. The company anticipates that its inventory position and sourcing flexibility will help maintain gross margin levels.
U.S. midstream and Process Solutions growth: Demand in U.S. midstream, including infrastructure expansions and gathering asset investments, is projected to remain strong. Process Solutions, strengthened by recent acquisitions, is expected to capture additional revenue from industrial and energy transition markets, such as water, wastewater, and data centers.
M&A and market adjacencies: DistributionNOW intends to pursue further acquisitions, particularly in U.S. Process Solutions, and seeks to grow in adjacent sectors like mining, chemicals, and renewable energy. Management noted that diversification efforts are designed to reduce reliance on upstream drilling and completion activity, mitigating downside risk from potential rig count declines.
Looking forward, the StockStory team will monitor (1) how effectively DistributionNOW passes on tariff-related cost increases to customers and preserves gross margins, (2) continued expansion and integration of recent acquisitions in international and Process Solutions markets, and (3) the pace of digital adoption and AI-driven process improvements. Progress in adjacent market penetration and the impact of rig count trends will also be watched closely.
DistributionNOW currently trades at a forward EV-to-EBITDA ratio of 10.3×. In the wake of earnings, is it a buy or sell? See for yourself in our full research report (it's free).
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
‘Time to Double Down,' Says Top Investor About Novo Nordisk Stock
It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company's share price has tumbled some 60% over the past twelve months. Though Novo Nordisk remains the dominant player in the burgeoning GLP-1 market, worries over a complex regulatory environment, lowered guidance, and increasing competition, among other concerns, have whittled away some of its support. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. And yet, the company's Q2 2025 earnings call last reflected rising sales of 18% during the first half of the year, increased operating profits of 29% for the first six months as well, and advancements with strategic R&D initiatives including an oral weight loss medicine. The market responded with a warmth that has been missing, and NVO's share price has increased by double digits since the earnings call. Top investor James Foord thinks a turnaround is indeed beckoning. 'The recent stock correction presents a rare long-term buying opportunity, supported by a strong pipeline, manufacturing expansion, and international momentum,' asserts the 5-star investor, who is among the top 2% of TipRanks' stock pros. The investor notes that the company succeeded in delivering strong numbers in Q2, with GLP-1 drugs leading the way. While sales for Ozempic – used to treat Type 2 diabetes – jumped by 35%, the Wegovy weight loss drug saw its sales increase by 67%. And it's not just the North American market which is gaining steam, points out Foord. Japan experienced a 91% increase in GLP-1 drugs in Q2. It is this dominance in the GLP-1 market which gives Foord plenty of bullish confidence in NVO going forward – especially as Wegovy aims for a 2026 tablet form. 'Novo has shown superior performance in their latest pill version of Wegovy versus Lily, and this is very encouraging,' adds Foord. With the company spending billions of dollars to increase production capabilities, including in North Carolina, and the potential for GLP-1 drugs to be used for additional morbidities such as Alzheimer's and cardiovascular disease, the investor predicts NVO is on the road to recovery. 'With new facilities coming online, oral drugs in development, and global demand still exploding, I see NVO not only rebounding but potentially doubling in the next few years,' concludes Foord. 'I'm buying more.' No surprise here, Foord is rating NVO a Strong Buy. (To watch James Foord's track record, click here) Though slightly more tempered, Wall Street is also optimistic about NVO. With 2 Buy ratings and 3 Holds, NVO enjoys a Moderate Buy consensus rating. Its 12-month average price target of $71.75 has an upside north of 40%. (See NVO stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
an hour ago
- Yahoo
Results: NCR Atleos Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
Explore NCR Atleos's Fair Values from the Community and select yours NCR Atleos Corporation (NYSE:NATL) investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beating expectations by 2.0% to hit US$1.1b. NCR Atleos also reported a statutory profit of US$0.60, which was an impressive 22% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Taking into account the latest results, NCR Atleos' six analysts currently expect revenues in 2025 to be US$4.35b, approximately in line with the last 12 months. Per-share earnings are expected to leap 47% to US$2.56. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$4.31b and earnings per share (EPS) of US$2.55 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. Check out our latest analysis for NCR Atleos With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 12% to US$44.67. It looks as though they previously had some doubts over whether the business would live up to their expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on NCR Atleos, with the most bullish analyst valuing it at US$60.00 and the most bearish at US$34.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that NCR Atleos is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.7% annualised growth until the end of 2025. If achieved, this would be a much better result than the 0.5% annual decline over the past year. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 8.0% annually for the foreseeable future. Although NCR Atleos' revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry. The Bottom Line The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for NCR Atleos going out to 2027, and you can see them free on our platform here. Plus, you should also learn about the 2 warning signs we've spotted with NCR Atleos (including 1 which is concerning) . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Fidelis Insurance Holdings' (NYSE:FIHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Fidelis Insurance Holdings Limited (NYSE:FIHL) will increase its dividend on the 26th of September to $0.15, which is 50% higher than last year's payment from the same period of $0.10. This makes the dividend yield 2.4%, which is above the industry average. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Fidelis Insurance Holdings' Projections Indicate Future Payments May Be Unsustainable Estimates Indicate Fidelis Insurance Holdings' Could Struggle to Maintain Dividend Payments In The Future Fidelis Insurance Holdings' Future Dividends May Potentially Be At Risk While it is great to have a strong dividend yield, we should also consider whether the payment is sustainable. Fidelis Insurance Holdings is not generating a profit, but its free cash flows easily cover the dividend, leaving plenty for reinvestment in the business. We generally think that cash flow is more important than accounting measures of profit, so we are fairly comfortable with the dividend at this level. EPS is forecast to rise very quickly over the next 12 months. Assuming the dividend continues along recent trends, we could see the payout ratio reach 222%, which is on the unsustainable side. View our latest analysis for Fidelis Insurance Holdings Fidelis Insurance Holdings Doesn't Have A Long Payment History It's not possible for us to make a backward looking judgement just based on a short payment history. This doesn't mean that the company can't pay a good dividend, but just that we want to wait until it can prove itself. Fidelis Insurance Holdings Could Grow Its Dividend The company's investors will be pleased to have been receiving dividend income for some time. Fidelis Insurance Holdings has impressed us by growing EPS at 8.0% per year over the past five years. Even though the company isn't making a profit, strong earnings growth could turn that around in the near future. As long as the company becomes profitable soon, it is on a trajectory that could see it being a solid dividend payer. In Summary Overall, this is probably not a great income stock, even though the dividend is being raised at the moment. The company is generating plenty of cash, which could maintain the dividend for a while, but the track record hasn't been great. We would probably look elsewhere for an income investment. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. As an example, we've identified 1 warning sign for Fidelis Insurance Holdings that you should be aware of before investing. Is Fidelis Insurance Holdings not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
